Video - Results from #10

REVIEW UroToday

Clinical Trials For My Patients - Bladder Cancer VL

Search

Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer (IMMORTAL) Details This phase II trial, Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer (IMMORTAL) investigates the impact of adding radiation therapy to immunotherapy compared to immunotherapy alone for metastatic urothelial cancer. Radiation therapy, specifically stereotactic body radiation therapy (SBRT), may shrink tumors but can have side effects. Immunotherapy with monoclonal a...
A Study to Improve the Diagnosis of Bladder Cancer - BladderPath Study - Jim Catto & Gary Steinberg Details With the oncological safety of TURBT unknown, staging inaccuracies are commonplace, and correct treatment of muscle-invasive bladder cancer is potentially delayed. The BladderPath study is looking at using a multiparametric magnetic resonance imaging (mpMRI) scan to diagnose bladder cancer that has grown into the muscle. Drs. Jim Catto and Gary Steinberg join Dr. Ashish Kamat in a discussion about...
Combining BCG and Intravesical Gemcitabine (GBIG) for Patients with BCG-Relapsing High-Grade NMIBC Cancer A Phase 1/2 Trial- Eugene Pietzak Details Eugene Pietzak, MD joins Ashish Kamat, MD MBBS, to discuss an investigator-initiated trial, "Combination BCG and Intravesical Gemcitabine (CBIG) in Patients with BCG Relapsing Non-Muscle Invasive Bladder Cancer" (NCT04179162) that is currently recruiting. Dr. Pietzak explains the rationale for the trial design and the background on the questions this trial seeks to understand, in the combination o...
Chemoradiation in Urothelial Carcinoma: The Herculean Effort Behind the SWOG 1806 Trial - Petros Grivas Details Alicia Morgans speaks with Petros Grivas to discuss the intricacies of the SWOG 1806 clinical trial, led by Dr. Parminder Singh. This multi-institutional study aims to evaluate the efficacy of adding atezolizumab, an anti-PD-L1 agent, to chemoradiation treatment in patients with localized muscle-invasive urothelial carcinoma. Dr. Grivas emphasizes the collaborative nature of this "Herculean effort...
Variant Histologies of Bladder Cancer - Petros Grivas Details Alicia Morgans is joined by Petros Grivas to discuss a unique study focusing on patients with variant histologies of bladder cancer. The study aims to improve complete response rates by combining chemotherapy with pembrolizumab in a neoadjuvant setting. With only 17 patients, it's a pilot study that tackles the difficulty in finding effective treatments for varying histologies such as squamous cel...
Phase II Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer - Michael Woods Details Joining Alicia Morgans, MD, MPH, is Michael Woods, MD, who is the leader of the Alliance trial A031803, a phase II trial studying how well gemcitabine with pembrolizumab works in treating patients with non-muscle invasive bladder cancer (NMIBC) who are unresponsive to bacillus Calmette-Guérin (BCG). This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients...
Genitourinary Cancers Symposium 2021 Trials in Progress TROPiCS-04 - Petros Grivas Details Petros Grivas discusses the upcoming ASCO GU 2021 meeting that opens on Thursday, February 11, 2021. Dr. Grivas will be presenting a "Trials in Progress" on the study of sacituzumab govitecan (IMMU-132) in metastatic or locally advanced unresectable urothelial cancer (TROPiCS-04). This is a Phase III, global, multicenter, open-label randomized controlled trial in which approximately 600 subjects w...